Patent ID: 11951171
Assignee: TIANJIN MEDICAL UNIVERSITY
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 3:
4. The drug delivery system product according to claim 2, further comprising a pharmacodynamically active molecule; said pharmacodynamically active molecule is selected from the group consisting of polypeptide, polynucleotide, and a small molecular compound which is covalently conjugated to the polypeptide EXP; wherein the polypeptide which is covalently conjugated to the polypeptide EXP is selected from the group consisting of muscle-targeting peptide M12, liver cancer-targeting peptide P47, brain-targeting peptide RVG and N1ND; wherein the polynucleotide which is covalently conjugated to the polypeptide EXP is neutral, uncharged PNA; or wherein the small molecule compound which is covalently conjugated to the polypeptide EXP is phosphorodiamidate morpholino oligomer (PMO).